このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response

2026年11月2日 更新者:Adaxion Therapeutics

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Subcutaneous and Intravenous ADX-001 in Healthy Adult Participants

This is a phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of subcutaneous and intravenous ADX-001 in healthy adult participants

調査の概要

状態

募集

条件

介入・治療

詳細な説明

ADX-001 is a new investigational medicine being developed to treat inflammatory diseases, such as inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, and certain rheumatic diseases, such as psoriatic arthritis.

The purpose of this study is to evaluate the safety and tolerability of ADX-001 in healthy adult volunteers. The study will also examine how the body processes the medicine, how the medicine affects the immune system, and whether the body develops antibodies against the medicine. The results of this study will help determine appropriate doses and dosing schedules for future studies in patients with inflammatory diseases.

研究の種類

介入

入学 (推定)

88

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • South Australia
      • Adelaide、South Australia、オーストラリア、5000
        • 募集
        • CMAX Clinical Research

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~55年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Provide informed consent - Be willing and able to sign a consent form after understanding the study and before any study-related procedures are performed.
  • Age - Be a healthy adult male or female aged 18 to 55 years.
  • Body weight and BMI - Have a Body Mass Index (BMI) between 18.0 and 32.0 kg/m². Weigh more than 50 kg and less than 120 kg.
  • For women who can become pregnant - Have a negative pregnancy test before participating.
  • Use highly effective birth control during the study and for 15 months after the last study dose.

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

  1. Medical Conditions

    • You have a serious or ongoing health condition affecting the heart, lungs, liver, kidneys, digestive system, hormones, nervous system, immune system, or mental health.
    • You have a history of severe allergic reactions, anaphylaxis, or are allergic to the study drug or its ingredients.
  2. Infections

    • You test positive for HIV, hepatitis B, or hepatitis C.
    • You have tuberculosis (TB), a history of TB, recent close contact with someone who has active TB, or a positive TB screening test.
    • You test positive for COVID-19 before receiving the study drug.
    • You have an active or long-term infection requiring treatment.
    • You have needed antibiotics or other anti-infective treatment within the last month.
    • You were hospitalized or required intravenous (IV) treatment for an infection within the last 3 months.
    • You have a history of certain recurring infections, such as shingles (herpes zoster).
    • You have a fever higher than 37.7°C during screening or within 7 days before dosing.
    • In some cases, minor abnormalities may be accepted if the study doctor considers them not clinically important.

4. Heart and Blood Pressure Problems 5. Previous Medications or Treatments

  • You have previously received medicines that target TNFα or IL-23.

  • You have received other biologic medicines within the last 6 months.

  • You have used medicines that significantly suppress the immune system within the required washout period.

  • You have recently used prescription or over-the-counter medications that could affect study results.

  • You received a live vaccine within the last 12 weeks or any other vaccine within the last 4 weeks.

  • You donated blood, plasma, or platelets too recently before joining the study.

    6. Alcohol or Drug Use. 7. Pregnancy and Reproductive Considerations

  • You are pregnant, breastfeeding, or planning to become pregnant during the study period.

  • You are unwilling to use the required birth control methods.

    8. Participation in Other Research Studies

  • You have recently participated in another clinical trial involving an investigational drug or device.

  • You have previously participated in this study.

    9. Ability to Participate

  • You are unable to understand the study requirements or provide informed consent.

  • You are unable or unwilling to follow study procedures and visit schedules.

    10. Conflict of Interest

  • You are an employee of the study sponsor or investigator, or an immediate family member of one.

    11. Other Safety Concerns

  • The study doctor believes that participating could put your health at risk, prevent you from completing the study, or affect the reliability of the study results.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:SAD Cohort 1-5

ADX-001 administered as a single dose according to the assigned cohort and route of administration (SC or IV).

ADX-001 administered every 4 weeks (Q4W) for a total of 4 doses according to the assigned cohort and route of administration (SC or IV).

Matching placebo administered by SC injection or IV infusion according to the route and dosing schedule of the assigned cohort.

実験的:MAD Cohort 6-9

ADX-001 administered as a single dose according to the assigned cohort and route of administration (SC or IV).

ADX-001 administered every 4 weeks (Q4W) for a total of 4 doses according to the assigned cohort and route of administration (SC or IV).

Matching placebo administered by SC injection or IV infusion according to the route and dosing schedule of the assigned cohort.

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
Incidence and severity of Treatment Emergent Adverse Events (TEAEs) of single and multiple doses of ADX-001 administered by subcutaneous and intravenous injection
時間枠:From first dose through Day 365 for participants receiving a single dose and through Day 505 for participants receiving multiple doses.
From first dose through Day 365 for participants receiving a single dose and through Day 505 for participants receiving multiple doses.

二次結果の測定

結果測定
時間枠
PK Parameters peak concentration (Cmax) - SAD
時間枠:Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
PK Parameters peak concentration (Cmax) - MAD
時間枠:Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Area under the concentration-time curve (AUC0-t) - SAD
時間枠:Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Area under the concentration-time curve (AUC0-t) - MAD
時間枠:Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Terminal elimination half-life (t1/2) - SAD
時間枠:Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Terminal elimination half-life (t1/2) - MAD
時間枠:Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Clearance (CL) - SAD
時間枠:Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Clearance (CL) - MAD
時間枠:Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Volume of distribution (Vz) - SAD
時間枠:Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Volume of distribution (Vz) - MAD
時間枠:Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Serum concentrations of free CD22L- SAD
時間枠:Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Serum concentrations of free CD22L- MAD
時間枠:Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Incidence of treatment-emergent anti-drug antibodies (ADA)
時間枠:From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Maximum observed serum concentration (Cmax) of ADX-001 by ADA status
時間枠:From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Minimum observed serum concentration (Cmin) of ADX-001 by ADA status
時間枠:From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Area under the serum concentration-time curve (AUC0-last) of ADX-001 by ADA status
時間枠:From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Area under the serum concentration-time curve over the dosing interval (AUCτ) of ADX-001 by ADA status
時間枠:From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Clearance (CL) of ADX-001 by ADA status
時間枠:From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Terminal elimination half-life (t½) of ADX-001 by ADA status
時間枠:From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Incidence of treatment-emergent adverse events by ADA status
時間枠:From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年10月20日

一次修了 (推定)

2027年7月29日

研究の完了 (推定)

2028年12月14日

試験登録日

最初に提出

2026年10月2日

QC基準を満たした最初の提出物

2026年10月11日

最初の投稿 (実際)

2026年10月15日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月4日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • ADX-001-CLN-01

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。